A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Active, not recruiting · Phase 3 · NCT04211337
Conditions: Medullary Thyroid Cancer
At a glance
- Research payments reported, 2025
- $376,756
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 291
About the trial
- Sponsor
- Loxo Oncology, Inc. (with Eli Lilly and Company)
- Tested
- Selpercatinib (drug), Cabozantinib (drug), Vandetanib (drug)
- Dates
- Started 2020-02-11; completion 2027-11
- Results posted
- Yes
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
From ClinicalTrials.gov, last updated 2026-03-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $376,756 in research payments for this study in 2025 (26 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lisle Nabell Hematology & Oncology · Birmingham, AL
- Mili Arora, MD Hematology & Oncology · Sacramento, CA
- Sasan Fazeli, M.D. Endocrinology & Diabetes · Duarte, CA
- Andrew G. Gianoukakis, M.D. Endocrinology & Diabetes · Torrance, CA
- Deborah J. Wong, M.D., PH.D. Hematology & Oncology · Los Angeles, CA
- Trisha M. Wise-draper, MD, PHD Hematology & Oncology · Indianapolis, IN
- Lori J. Wirth, MD Medical Oncology · Boston, MA
- Francis P. Worden, MD Medical Oncology · Ann Arbor, MI
- Vineeth K. Sukrithan, MD Medical Oncology · Columbus, OH
- Marcia S. Brose, MD Medical Oncology · Philadelphia, PA
- Eric J. Sherman, MD Medical Oncology · Philadelphia, PA
- Justine Y. Bruce Medical Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Board of Regents of the Univ of Wisconsin Systm $99,482
- Memorial Sloan-Kettering $55,837
- University of California Davis Medical Center, CA $32,559
- University of Alabama Hospital, AL $31,022
- City of Hope National Medical Ctr $28,927
- Ronald Reagan UCLA Medical Center, CA $28,248
- $24,425
- Thomas Jefferson University $23,216
- The Ohio State University $15,475
- University of Michigan Health System, MI $10,965
- University of Cincinnati Physicians $10,278
- Dana Farber PArtners Cancer Care Inc $9,320
- Los Angeles Biomedical $7,003
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.